4-benzyl 1-t-butyl L-aspartate | 94347-11-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天然氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-benzyl 1-t-butyl L-aspartate
• 英文别名: 4-benzyl 1-(tert-butyl) L-aspartate；H-Asp(OBzl)-OtBu；H-Asp(OBn)-O-t-Bu；4-O-benzyl 1-O-tert-butyl (2S)-2-aminobutanedioate
• CAS: 94347-11-2
• 化学式: C₁₅H₂₁NO₄
• 分子量: 279.336
• InChiKey: OFNHAOOUAHIECU-LBPRGKRZSA-N

物化性质

• 沸点：
  381.3±32.0 °C(Predicted)
• 密度：
  1.122±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2922499990
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: L-Aspartic acid beta-benzyl ester alfa-t-butyl ester HCl
Synonyms: H-Asp(OBzl)-OtBu HCl

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: L-Aspartic acid beta-benzyl ester alfa-t-butyl ester HCl
CAS number: 94347-11-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H21NO4.ClH
Molecular weight: 315.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-benzyl 1-t-butyl L-aspartate 在 4-二甲氨基吡啶 、 palladium on activated charcoal 4-二甲氨基吡啶 、 dimethyl sulfide borane 、 氢气 、 dipyridine chromium trioxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 24.0h， 生成 tert-butyl L-2-[bis(tert-butoxycarbonyl)amino]-4-oxo-butanoate
  参考文献：
  名称：

  Asymmetric synthesis of differentially protected meso-2,6-diaminopimelic acid

  摘要：

  meso-2,6-Diaminopimelic acid, an important linking component of bacterial cell walls and a biosynthetic precursor of L-lysine has been prepared differentially protected in a stereospecific manner from both L-aspartic and L-glutamic acid. The key step to establish the second chiral center involves the asymmetric reduction of a pyruvate moiety with Alpine-Borane(R). S-2-Amino-6-oxopimelic acid, the hydrolyzed open chain form of tetrahydrodipicolinic acid, a biosynthetic precursor of meso-2,6-diaminopimelic acid, was also prepared via deprotection of the key pyruvate intermediate. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)01844-0
• 作为产物：
  描述：

  芴甲氧羰基-L-天冬氨酸-1-叔丁酯 在 哌啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 1.0h， 生成 4-benzyl 1-t-butyl L-aspartate
  参考文献：
  名称：

  基于羧酸的小分子STAT3抑制剂的接头变异与结构-活性关系分析

  摘要：

  研究了已报道的苯甲酸（SH4-54），水杨酸（BP-1-102）和苯并异羟肟酸（SH5-07）的STAT3抑制剂的分子决定因素，以设计优化的类似物。所有三个导联均基于N-甲基甘氨酰胺支架，其两个胺基缩合成三个不同的官能团。甘氨酰胺支架的三个功能和CH 2基团分别进行了修饰。五氟苯或环己基苯的取代，或用杂环成分（含氮和氧元素）取代芳族羧酸或异羟肟酸基序的苯环，均会降低效能。值得注意的是，Ala-linker类似物1a和2v，以及在手性中心均具有（R）构型的基于Pro的衍生物5d在体外具有更高的抑制活性和针对STAT3 DNA结合活性的选择性，IC 50为3.0±0.9、1.80±0.94和2.4分别为±0.2μM。化合物1a，2v，5d和其他类似物在人乳腺癌和黑色素瘤细胞系中抑制STAT3组成型STAT3的磷酸化和激活，并在体外阻断肿瘤细胞的活力，生长，集落形成和迁移。基于专业的模拟，5h具

  DOI：

  10.1021/acsmedchemlett.7b00544

文献信息

• The in vitro transport of model thiodipeptide prodrugs designed to target the intestinal oligopeptide transporter, PepT1
  作者：David Foley、Myrtani Pieri、Rachel Pettecrew、Richard Price、Stephen Miles、Ho Kam Lam、Patrick Bailey、David Meredith

  DOI：10.1039/b909221h

  日期：——

  A thiodipeptide carrier system is shown to be effective at enabling a range of covalently bound molecules, including benzyl, benzoyl and ibuprofen conjugates, to be transported via the intestinal peptide transporter PepT1, demonstrating its potential as a rational drug delivery target.

  研究表明，硫代二肽载体系统能有效促进一系列共价结合的分子（包括苄基、苯甲酰基和布洛芬衍生物）通过肠道肽转运体PepT1进行转运，显示了其作为合理药物传递靶点的潜力。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2018006063A1

  公开（公告）日：2018-01-04

  Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

  用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是，这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
• Targeting ketone drugs towards transport by the intestinal peptide transporter, PepT1
  作者：David Foley、Patrick Bailey、Myrtani Pieri、David Meredith

  DOI：10.1039/b818606e

  日期：——

  Thiodipeptide prodrugs of the ketone nabumetone are shown to have affinity for, and be transported by, PepT1 in vitro.

  酮基nabumetone的硫代二肽前药显示出在体外对PepT1具有亲和性，并能被其转运。
• [EN] GLP-1 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR DU GLP-1
  申请人：CELGENE INTERNAT II SARL

  公开号：WO2016094729A1

  公开（公告）日：2016-06-16

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "^^^^" represents either or both the R and S form of the compound) (I) where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

  提供了一些化合物，这些化合物可以调节胰高血糖素样肽1（GLP-1）受体，以及它们的合成方法，以及它们的治疗和/或预防使用方法。这类化合物可以单独作为GLP-1受体的调节剂或增强剂，或者与肠促胰岛素肽（如GLP-1(7-36)和GLP-1(9-36)）一起使用，或者与基于肽的治疗方法（如艾塞那肽和利拉鲁肽）一起使用，并具有以下一般结构（其中"^^^^"代表化合物的R和S形式中的一个或两个）(I) 其中A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p和q的定义如下。
• The synthesis of pyrimidin-4-yl substituted α-amino acids. A versatile approach from alkynyl ketones
  作者：Robert M. Adlington、Jack E. Baldwin、David Catterick、Gareth J. Pritchard

  DOI：10.1039/a806741d

  日期：——

  The reaction of amidines with α-amino acid alkynyl ketones is shown to be a versatile route to pyrimidin-4-yl substituted α-amino acids. This route is also applicable to a parallel synthesis approach and has allowed the formation of a range of pyrimidin-4-yl substituted α-amino acids, including the naturally occurring α-amino acid L-lathyrine 4.

  am与α-氨基酸炔基酮的反应显示出是嘧啶-4-基取代的α-氨基酸的通用途径。该途径也适用于平行合成方法，并允许形成一定范围的嘧啶-4-基取代的α-氨基酸，包括天然存在的α-氨基酸L-山thy碱4。